胸腺肽类药物用于预防或治疗新型冠状病毒肺炎的可能性——基于既往冠状病毒预防和治疗的总结

Evaluation of the Possibility of Thymosin for COVID-19 Prevention and Treatment:Based on the Summary of Previous Coronavirus Prevention and Treatment

目的:本研究通过对胸腺肽类药物既往用于预防和治疗冠状病毒肺炎的研究进行梳理总结,以期探索胸腺肽类药物用于预防或治疗新型冠状病毒肺炎的可能性。方法:在中国期刊全文数据库(CNKI)、万方数据库(Wanfang Data)、维普中文科技期刊全文数据库(VIP)、中国生物医学文献数据库(CBM)、Cochrane library、PubMed等数据库全面检索相关研究文献。对纳入文献进行总结分析,提取出与预防或治疗新型冠状病毒肺炎相关的研究数据。结果:系统文献检索总共得到文献116篇,初步筛选后剩下38篇,最终纳入文献24篇。结果显示,胸腺肽类药在新型冠状病毒肺炎的早期治疗可能具有一定的效果,在严重肺损害阶段不建议使用;尚无证据显示其在预防方面的作用,健康人群盲目使用可能会增加感染的风险,而对本身免疫力功能低下及有相关适应证的患者可以遵循医嘱使用。结论:胸腺肽类药物可以作为一种试验性疗法用于新型冠状病毒肺炎,并应该为此尽快开展随机对照试验和真实世界临床研究,进一步探索胸腺肽类药物用于新型冠状病毒肺炎的临床效果。

Objective:To assess the previous researches of thymosin in the treatment and prevention of coronavirus pneumonia,to provide evidence for Coronavirus Disease 2019(COVID-19)prevention and treatment.Methods:Researchers electronically searched Chinese and English researches in the Cochrane library,PubMed,CNKI,WanFang Data,VIP and CBM databases from January 2003 to February 2020.To summarize and analyze the included literature and extract research data related to the prevention or treatment of COVID-19.Results:The review found 116 related studies,then narrowed down to 38 studies.Finally 24 studies were included.Results of previous studies showed that although thymosin may be effective as an experimental therapy in COVID-19 early treatment,prescribed medication should in accordance with the symptom.There was no evidence in disease prevention.Thymosin might increase the infection probability of healthy people but decrease infection risk of suitable patients or people with hypoimmunity.Clinical application of thymosin on COVID-19 treatment and prevention should follow doctor’s advice.Conclusion:Thymosin could be effective in COVID-19 treatment,and to further explore the clinical effects of thymosin drugs on COVID-19,the abovementioned conclusion should be verified by conducting high-quality Randomized Control Trials(RCT)and real-world studies.